Zetia Cost in Rhode Island 2026: Cash Price, Medicaid, and Generic Options

What Does Zetia Actually Cost in Rhode Island in 2026?

Generic ezetimibe runs about $15 per month at most Rhode Island retail pharmacies when purchased with a GoodRx-style coupon or a warehouse-club membership, making it one of the more affordable lipid-lowering agents in the state. Brand-name Zetia carries a Merck list price near $380 per month, though almost no cash-paying patient pays that figure after discounts.

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50% [1]. The drug was approved by the FDA in 2002 and has been available as a generic since 2017, which is the primary driver of its low cash price today [2].

The landmark IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite of cardiovascular death, major coronary events, and stroke by 6.4% relative to simvastatin alone (32.7% vs. 34.7%; P<0.001) over a median follow-up of 6 years [3]. That trial settled the decade-long debate about whether lowering LDL-C via non-statin mechanisms translates to fewer cardiac events.

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states: "In patients at high cardiovascular risk with LDL-C levels remaining above 70 mg/dL despite maximally tolerated statin therapy, addition of ezetimibe is reasonable" [4]. That guidance has made ezetimibe a common second-line add-on for Rhode Island patients whose LDL-C targets remain unmet on statins alone.

At the 10 mg once-daily dose, ezetimibe reduces LDL-C by approximately 18 to 25% as monotherapy and by an additional 15 to 20% when added to a statin [5]. The side-effect profile is mild; the most commonly reported adverse events are upper respiratory infections, diarrhea, and arthralgia, each occurring in fewer than 4% of patients in controlled trials [2].

Rhode Island Medicaid Coverage for Ezetimibe

Rhode Island Medicaid covers ezetimibe, but a prior authorization (PA) is required before the claim will process at the pharmacy. The PA requirement reflects Rhode Island's preferred drug list (PDL), which tiers ezetimibe as a non-preferred agent in some managed care organization (MCO) formularies because generic statins are available at lower total cost.

To obtain PA approval through Rhode Island Medicaid, the prescribing clinician typically must document that the patient has an inadequate LDL-C response to at least one maximally tolerated statin, or that statins are contraindicated or not tolerated due to adverse effects such as myopathy [6]. Diagnosis codes supporting familial hypercholesterolemia (FH) can also support PA approval. Rhode Island Medicaid's PA decisions are governed by the Rhode Island Executive Office of Health and Human Services (EOHHS), which publishes its clinical criteria at its official portal [7].

Once PA is granted, copays for Medicaid beneficiaries are nominal, often $0 to $3.65 per fill depending on the MCO. Patients enrolled in RIte Care (the state's Medicaid managed care program) should confirm ezetimibe's tier placement directly with their assigned plan, as UnitedHealthcare Community Plan of Rhode Island, Neighborhood Health Plan of Rhode Island, and Tufts Health Unify each maintain separate formularies.

The American College of Cardiology 2022 Expert Consensus Decision Pathway notes that "ezetimibe should be considered before PCSK9 inhibitors owing to its substantially lower cost and oral administration route" [8]. That hierarchy supports Medicaid PA reviewers in approving ezetimibe prior to stepping up to injectable agents like evolocumab or alirocumab, which carry list prices exceeding $500 per month.

Patients denied PA on a first submission have the right to an internal appeal followed by an external independent review. The Rhode Island Department of Human Services processes Medicaid appeal requests within 30 days for standard reviews and within 72 hours for expedited reviews when the prescriber certifies that a delay would seriously jeopardize the patient's health [7].

Is Compounded Ezetimibe Legal in Rhode Island?

Compounded ezetimibe is legally available in Rhode Island through licensed 503A pharmacies, which compound medications for individual patients based on a valid prescription from a licensed prescriber. The cost to patients at some 503A pharmacies is reported near $0 per month when bundled with a telehealth membership or care plan, though individual pharmacy pricing varies.

The FDA distinguishes 503A pharmacies (patient-specific compounding) from 503B outsourcing facilities (large-scale, non-patient-specific compounding) [9]. Ezetimibe is not on the FDA's 503B Bulk Drug Substances list and is not FDA-approved for commercial compounding at scale. However, 503A pharmacies in Rhode Island may compound ezetimibe for individual patients when a prescriber determines a commercially available product does not meet the patient's specific clinical needs, such as a patient with a documented allergy to a tablet excipient or a pediatric patient requiring a suspension formulation [9].

Rhode Island's pharmacy compounding oversight falls under the Rhode Island Board of Pharmacy, which enforces United States Pharmacopeia (USP) Chapter 795 standards for non-sterile compounding [10]. A 503A pharmacy operating in Rhode Island must hold an active state license and comply with both state regulations and federal DSHEA and FDCA provisions.

Patients considering compounded ezetimibe should verify the pharmacy's license on the Rhode Island Department of Health provider directory and ask for a certificate of analysis (CoA) for each batch. The FDA has warned that compounded drugs do not undergo the same pre-market review for safety, efficacy, or manufacturing quality as FDA-approved products [9], so due diligence matters.

Telehealth Prescribing of Ezetimibe in Rhode Island

Telehealth prescribing of ezetimibe is permitted in Rhode Island. A Rhode Island-licensed prescriber, including physicians, nurse practitioners, and physician assistants with prescriptive authority, may assess a patient via synchronous audio-video telehealth and issue a prescription for ezetimibe without a prior in-person visit, provided the prescriber complies with standard-of-care requirements for lipid management [11].

Rhode Island adopted permanent telehealth parity legislation following the COVID-19 public health emergency. Rhode Island General Laws Section 27-81 requires commercial insurers to reimburse telehealth services at parity with in-person visits for covered benefits [12]. That parity rule means a patient receiving a telehealth lipid consultation and an ezetimibe prescription through a service like HealthRX pays the same specialist copay they would for an in-person visit.

Before prescribing ezetimibe via telehealth, a clinician should review the patient's baseline lipid panel, liver function tests, and current medication list. A repeat lipid panel four to twelve weeks after starting ezetimibe confirms LDL-C response, as recommended by the ACC/AHA 2018 Cholesterol Guideline [13]. Telehealth platforms that integrate lab ordering allow this follow-up to occur without a separate clinic visit.

For patients without commercial insurance who want telehealth access, several direct-pay telehealth services in Rhode Island offer subscriptions that include a bundled pharmacy price for generic ezetimibe. At approximately $15 per month for the medication plus a low monthly membership fee, total out-of-pocket cost remains well below the brand-name Zetia list price [2].

How the Merck Zetia Savings Card Works in Rhode Island

Merck offers a Zetia savings card for commercially insured patients that can reduce the brand-name copay to as low as $5 per month. The savings card is administered through Merck's patient assistance infrastructure and is available to Rhode Island residents who have commercial insurance that covers Zetia but face a high copay or coinsurance obligation.

The card does not apply to patients covered by any federal or state government program, including Rhode Island Medicaid, Medicare Part D, Tricare, or the Veterans Affairs formulary [2]. That restriction is standard for manufacturer copay assistance programs under the Anti-Kickback Statute safe harbors applicable to government program beneficiaries.

Rhode Island patients with commercial plans who still face high Zetia costs despite the savings card should ask their prescriber to switch the prescription to generic ezetimibe 10 mg. The generic is therapeutically equivalent to brand Zetia, carries an A-B rating from the FDA's Orange Book [14], and costs roughly 96% less at cash-pay prices. There is no clinical reason to prefer brand Zetia over the generic formulation.

Patients without any insurance coverage may qualify for Merck's patient assistance program (PAP), which provides free brand-name Zetia to qualifying low-income patients. Income thresholds and application requirements are detailed on Merck's official PAP portal and are updated annually. Rhode Island residents can also access NeedyMeds and the Partnership for Prescription Assistance as additional referral resources.

Comparing All Cost Options for Rhode Island Patients

Generic ezetimibe at $15 per month is the default starting point for most cash-paying Rhode Island patients. Discount platforms including GoodRx, RxSaver, and Blink Health frequently post prices between $10 and $18 for a 30-day supply of ezetimibe 10 mg at Rhode Island pharmacies such as CVS (with dozens of RI locations), Walgreens, Rite Aid, and independent community pharmacies in Providence, Cranston, and Warwick.

The table below summarizes cost pathways for a Rhode Island patient needing ezetimibe 10 mg once daily for 30 days.

| Access pathway | Estimated monthly cost | Key requirement | |---|---|---| | Generic ezetimibe, cash + coupon | ~$15 | Valid prescription | | Brand Zetia, Merck savings card | ~$5 copay | Commercial insurance, not Medicaid/Medicare | | Rhode Island Medicaid (post-PA) | $0 to $3.65 | Prior authorization approval | | 503A compounded ezetimibe | ~$0 to $30 | Prescriber clinical rationale, licensed 503A pharmacy | | Brand Zetia, no assistance | ~$380 | None | | Merck PAP (free brand) | $0 | Income qualification |

Warehouse clubs (Costco and BJ's Wholesale, both present in Rhode Island) dispense generic ezetimibe to members and non-members at their pharmacy counters and consistently post prices near or below $10 for a 90-day supply when combined with a GoodRx coupon. Calling ahead to confirm current pricing before making the trip saves time.

Ezetimibe Dosing, Drug Interactions, and Safety Considerations

The standard adult dose of ezetimibe is 10 mg once daily, taken at any time of day with or without food [2]. No dose adjustment is needed for mild to moderate renal impairment or mild hepatic impairment. Ezetimibe should not be used in patients with moderate to severe hepatic impairment, as the drug undergoes extensive glucuronidation in the liver and intestine [2].

Clinically significant drug interactions are limited. Cyclosporine increases ezetimibe exposure (AUC) by approximately 3.4-fold and requires monitoring [2]. Bile acid sequestrants such as cholestyramine and colesevelam reduce ezetimibe absorption by about 55%; administering ezetimibe at least 2 hours before or 4 hours after the sequestrant preserves full absorption [2]. Fibrates modestly increase ezetimibe glucuronide exposure, and fenofibrate is generally considered acceptable in combination, while gemfibrozil is used cautiously given modest cholelithiasis risk with combined cholesterol reduction [15].

The SHARP trial (N=9,438) tested simvastatin 20 mg plus ezetimibe 10 mg versus placebo in patients with chronic kidney disease and showed a 17% proportional reduction in major atherosclerotic events (11.3% vs. 13.4%; P<0.001) [16]. That finding extended ezetimibe's evidence base to patients with CKD, a population that includes a meaningful proportion of Rhode Island's Medicaid enrollees.

Rhabdomyolysis has not been independently associated with ezetimibe monotherapy in randomized controlled trial data, though myopathy has been observed when ezetimibe is combined with high-dose statins [3]. Routine creatine kinase (CK) monitoring is not required per current ACC/AHA guidelines unless patients report muscle symptoms [13].

Liver enzyme elevations (ALT or AST more than three times the upper limit of normal) occurred in 1.3% of patients receiving ezetimibe plus statin versus 0.4% on statin monotherapy in pooled trial data [2]. Baseline liver function testing before initiation and follow-up if symptoms develop represents standard clinical practice per ACC/AHA 2018 guidance [13].

Why LDL-C Lowering With Ezetimibe Matters for Rhode Island Patients

Rhode Island's age-adjusted cardiovascular disease mortality rate tracks slightly above the national median according to CDC WONDER data [17]. Hyperlipidemia is a modifiable driver of that burden, and achieving LDL-C targets with well-tolerated, affordable therapy is directly relevant to population health in the state.

A meta-analysis by Cannon et al. published in the Journal of the American Medical Association (2015, N=49,123 across statin trials) confirmed that each 1 mmol/L (approximately 38.7 mg/dL) reduction in LDL-C reduces major vascular events by approximately 22%, regardless of the agent used to achieve the reduction [18]. Ezetimibe, by adding a complementary mechanism to statins, can push LDL-C toward guideline targets of below 70 mg/dL in high-risk patients and below 55 mg/dL in very-high-risk patients per the 2019 ESC/EAS guidelines, which Rhode Island clinicians frequently reference alongside ACC/AHA documents [19].

For a patient in Rhode Island who is already on atorvastatin 40 mg but whose LDL-C remains at 95 mg/dL, adding ezetimibe 10 mg could be expected to bring LDL-C to approximately 75 to 80 mg/dL, a clinically meaningful reduction achievable for $15 per month without changing the statin or stepping up to a PCSK9 inhibitor costing hundreds of dollars more [5].

The ACC 2022 Expert Consensus Decision Pathway recommends ezetimibe as the first non-statin add-on for patients not at LDL-C goal before considering PCSK9 inhibitors, specifically because of the cost differential [8]. That consensus position makes ezetimibe the practical choice for most Rhode Island patients regardless of payer status.